Literature DB >> 7117057

Colonoscopy: its role in cancer of the colon and rectum.

J C Reilly, L C Rusin, F J Theuerkauf.   

Abstract

In order to determine the feasibility, yield, and impact of routine total colonoscopy on the management of large-bowel cancer, 157 cancer patients underwent 175 colonoscopic procedures; 13.6 per cent of the cancers had been missed on double-contrast barium enema examination. Among 92 patients undergoing perioperative colonoscopy, the lesion was reached in 90 per cent and the cecum in 60 per cent; 7.6 per cent demonstrated synchronous cancers, all curable, and all missed on barium-enema examination. Seventy-eight patients underwent colonoscopy at an average of 3.7 years after treatment of the index cancer; 7.7 per cent demonstrated metachronous cancers, all curable, two-thirds of which were missed on barium-enema examination. Benign polyps were noted in 62 per cent of the patients studied; 77 per cent of those polyps, 1 cm or greater in size, were missed on barium-enema examination. Polyps were found proximal to the cancer in 60 per cent of the patients with polyps. Approximately 85 per cent of those with multiple cancers demonstrated benign polyps. Preoperative total colonoscopy with periodic postoperative colonoscopy at an interval of three to five years are essential in the reliable detection of synchronous cancers and for the detection of metachronous cancers at an earlier, more favorable stage.

Entities:  

Mesh:

Year:  1982        PMID: 7117057     DOI: 10.1007/bf02564161

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  9 in total

1.  Symposium: The management of recurrent colorectal cancer.

Authors:  F F Attiyeh; H Ellis; M Killingback; G D Oates; P F Schofield; H J Staab; G Steele; P H Sugarbaker
Journal:  Int J Colorectal Dis       Date:  1986-07       Impact factor: 2.571

2.  Future requirements for colonoscopy in Britain. Report by the Endoscopy Section Committee of the British Society of Gastroenterology.

Authors: 
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

3.  Do synchronous adenomas influence prognosis after radical surgery for colorectal carcinoma? A prospective study.

Authors:  O Kronborg; E Hage; C Fenger; E Deichgraeber
Journal:  Int J Colorectal Dis       Date:  1986-04       Impact factor: 2.571

4.  Synchronous colorectal cancer in an Oriental population.

Authors:  K W Eu; F Seow-Choen; H S Goh
Journal:  Int J Colorectal Dis       Date:  1993-12       Impact factor: 2.571

5.  Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II).

Authors:  R J Fitzgibbons; H T Lynch; G V Stanislav; P A Watson; S J Lanspa; J N Marcus; T Smyrk; M D Kriegler; J F Lynch
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

6.  A comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial polyposis coli, and de novo cancer.

Authors:  A J Greenstein; G Slater; T M Heimann; D B Sachar; A H Aufses
Journal:  Ann Surg       Date:  1986-02       Impact factor: 12.969

7.  Concordant DNA methylation in synchronous colorectal carcinomas.

Authors:  Kazuo Konishi; Lanlan Shen; Jaroslav Jelinek; Yoshiyuki Watanabe; Saira Ahmed; Kazuhiro Kaneko; Mari Kogo; Toshihumi Takano; Michio Imawari; Stanley R Hamilton; Jean-Pierre J Issa
Journal:  Cancer Prev Res (Phila)       Date:  2009-09-08

8.  Six-year results of annual colonoscopy after resection of colorectal cancer.

Authors:  G Juhl; G M Larson; R Mullins; S Bond; H C Polk
Journal:  World J Surg       Date:  1990 Mar-Apr       Impact factor: 3.352

9.  Synchronous colorectal neoplasias: our experience about laparoscopic-TEM combined treatment.

Authors:  Alessandro Spizzirri; Marco Coccetta; Roberto Cirocchi; Francesco La Mura; Vincenzo Napolitano; Maurizio Bravetti; Daniele Giuliani; Angelo De Sol; Eleonora Pressi; Stefano Trastulli; Micol Sole Di Patrizi; Nicola Avenia; Francesco Sciannameo
Journal:  World J Surg Oncol       Date:  2010-11-25       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.